skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Immuno-oncology (IO) is one of the most active area of clinical development. In the past few years, the IO clinical landscape has shifted towards combination trials which are trials that investigate IO therapies in combination with other therapies. To address this shift in the IO clinical trial landscape, Trialtrove has added three new IO combination tags to Trialtrove records that enable easy retrieval of IO combination trials. These tags capture the most common types of IO combination trials:

 

IO/IO Combination - clinical trials that evaluate the combination of two or more immuno-oncology drugs

IO/Targeted Combination - clinical trials that evaluate the combination of at least one immuno-oncology drug and at least one drug acting via a specific molecular target

IO/Cytotoxic Combination - clinical trials that evaluate the combination of at least one immuno-oncology drug and at least one drug acting as a broad-spectrum, cytotoxic agent

 

While all relevant Trialtrove records now contain the new IO tags, they are exclusively searchable using the next generation of Trialtrove. To introduce this enhancement, we compiled some key insights about IO combination trials and a visual overview of the IO competitive landscape.

 

 

 

 

 

Source: Trialtrove, data retrieved September 14, 2017 Authors: Maria A. Berezina, PhD and Rachel Meighan-Mantha, PhD Methodology: Combination trials included only those trials evaluating an IO drug or therapy in combination with another drug or therapy. Trials evaluating an IO drug or therapy alone or only with a non-drug intervention such as radiotherapy or surgery were categorized as Monotherapy trials. Initiation date was used for the charts with "Years".

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free   : +1 888 670 8900  
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (20) 805 20700
  • Australia        : +61 2 8705 6907

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now